Moving remote: the post-pandemic clinical trial

The restrictions on movement and normal interaction owing to COVID-19 pose a distinct challenge to the traditional clinical trial model, as patients, investigators and clinical staff are either confined to their homes or seeking to avoid healthcare settings.    Those running clinical trials over the past weeks have had to adapt rapidly by fast-tracking digital capabilities to ensure continued delivery. With the future of existing trials hanging in the balance, some have been pivoting to remote delivery – sometimes in the space of under a week.   Speaking at eyeforpharma Virtual, a digital version of the Barcelona event which can be accessed for free online athttps://virtual.eyeforpharma.com, experts in virtual trial delivery discuss the implications and opportunities for organisational reform, telemedicine, and new trial models that will arise from the crisis.   Pivoting to remote delivery“The world has changed radically over the past couple of months to weeks,” says Michelle Longmire, CEO of digital trial platform Medable, which has been working with pharma and biotech companies, CROs and academic research centres to shift standard clinical trial methodologies to telemedicine.   “The first challenge we were faced with was clinical trials in-flight, where patients were coming in for face-to-face visits and suddenly – specifically in Italy – you had a number of sites which were no longer available for physical visits. Over the last couple of weeks, we ' v...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news